# US 2004/0023882 A1 · PTH derivatives resistant to skin proteases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0023882 A1
- Document ID: US20040023882A1
- Status: Published application
- Kind: A1
- Application number: 10/440,473
- Filed: 2003-05-16
- Published: 2004-02-05
- Earliest claimed: 2002-05-16
- Inventors: Krishna G. Peri; Kim High; Annie Bergeron; Serge Moffett; Thierry Abribat
- Web page: https://patentgrep.com/patent/US20040023882A1

## CPC

- C07K 14/635: Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Protease-resistant analogues of biologically active derivatives of human PTH are described. These analogs are intended for use in therapeutic preparations for the treatment of various medical conditions in which bone loss is encountered or is susceptible of being encountered. The analogs specified are hPTH(1-34) and hPTH(1-31). More particularly, protease-resistant analogs of PTH adapted for transdermal administration are described.

## Claims

### Claim 1

A peptide comprising the following sequence:
1 H-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly- Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu- Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-NHR
wherein R is selected from the group consisting of a hydrogen atom, lower alkyl, lower alkenyl, substituted lower alkyl, substituted lower alkenyl, lower cycloalkylalkenyl, arylalkyl, substituted arylalkyl, lower arylalkyl, substituted lower arylalkyl, arylalkylenyl, substituted arylalkenyl and heteroarylalkenyl groups:

### Claim 2 (depends on 1)

A peptide as defined in claim 1, wherein R is a hydrogen atom.

### Claim 3 (depends on 1)

A peptide as defined in claim 1, wherein R is propyl.

### Claim 4 (depends on 1)

A peptide as defined in claim 1 wherein R is phenylpropyl.

### Claim 5 (depends on 1, 2, 3, 4)

An admixture comprising the peptide as defined in any one of claims 1 to 4 and a or more pharmaceutically acceptable carrier or excipients.

### Claim 6 (depends on 1, 2, 3, 4)

A pharmaceutical composition comprising from about 10 μg to about 100 mg of the peptide as defined in any one of claims 1 to 4 and a or more pharmaceutically acceptable carriers or excipients.

### Claim 7 (depends on 6)

A method for treating or preventing diseases or conditions involving loss of bone mineral, comprising administering a therapeutically effective amount of the pharmaceutical composition as defined in claim 6 to a patient in need thereof.

### Claim 8 (depends on 7)

The method of claim 7, wherein said diseases or conditions are selected from the group consisting of dental disease, osteoporosis and malignancy.

### Claim 9 (depends on 8)

The method as defined in claim 8, wherein the loss of bone mineral is due to dental disease.

### Claim 10 (depends on 8)

The method as defined in claim 8, wherein the loss of bone mineral is due to osteoporosis.

### Claim 11 (depends on 8)

The method as defined in claim 8, wherein the loss of bone mineral is due to malignancy.

### Claim 12 (depends on 7, 8, 9, 10, 11)

The method as defined in any one of claims 7 to 11, wherein said pharmaceutical composition effects replacement of bone mineral.

### Claim 13

A peptide comprising the following sequence:
2 H-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly- Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu- Arg-Lys-Lys-Leu-Gln-Asp-Val-NHR
wherein R is selected from the group consisting of a hydrogen atom, lower alkyl, lower alkenyl, substituted lower alkyl, substituted lower alkenyl, lower cycloalkylalkenyl, arylalkyl, substituted arylalkyl, lower arylalkyl, substituted lower arylalkyl, arylalkylenyl, substituted arylalkenyl and heteroarylalkenyl groups.

### Claim 14 (depends on 13)

A peptide as defined in claim 13, wherein R is a hydrogen atom.

### Claim 15 (depends on 13)

A peptide as defined in claim 13, wherein R is propyl.

### Claim 16 (depends on 13)

A peptide as defined in claim 13, wherein R is phenylpropyl.

### Claim 17 (depends on 13, 14, 15, 16, 17)

An admixture comprising the peptide as defined in any one of claims 13 to 17 and a or more pharmaceutically acceptable carriers or excipients.

### Claim 18 (depends on 13, 14, 15, 16, 17)

A pharmaceutical composition comprising from about 10 μg to about 100 mg of the peptide as defined in any one of claims 13 to 17 and a or more pharmaceutically acceptable carriers or excipients.

### Claim 19 (depends on 18)

A method for treating or preventing diseases or conditions involving loss of bone mineral, comprising administering a therapeutically effective amount of the pharmaceutical composition as defined in claim 18 to a patient in need thereof.

### Claim 20 (depends on 19)

The method of claim 19, wherein said diseases or conditions are selected from the group consisting of dental disease, osteoporosis and malignancy.

### Claim 21 (depends on 19)

The method as defined in claim 19, wherein the loss of bone mineral is due to dental disease.

### Claim 22 (depends on 19)

The method as defined in claim 19, wherein the loss of bone mineral is due to osteoporosis.

### Claim 23 (depends on 19)

The method as defined in claim 19, wherein the loss of bone mineral is due to malignancy.

### Claim 24 (depends on 19, 20, 21, 22, 23)

The method as defined in any one of claims 19 to 23, wherein said pharmaceutical composition effects replacement of bone mineral.

### Claim 25 (depends on 1)

A peptide as defined in claim 1, consisting of the following sequence:
3 H-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly- Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu- Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-NHR

### Claim 26 (depends on 13)

A peptide as defined in claim 13, consisting of the following sequence:
4 H-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly- Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu- Arg-Lys-Lys-Leu-Gln-Asp-Val-NHR
